Skip to main content

Advertisement

Log in

Options for the Treatment of Mucinous Ovarian Carcinoma

  • Gynecologic Cancers (LA Cantrell, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Complete surgical resection is the gold-standard treatment for all mucinous ovarian carcinoma (MOC) cases. Advanced-stage disease is often additionally treated with adjuvant platinum-based chemotherapy; however, these were developed largely against the more common high-grade serous ovarian carcinoma and have low efficacy in treating MOC. More effective therapeutics are needed to treat late-stage and platinum-resistant tumors; however, traditional drug development and clinical trial paradigms are a major challenge for such a rare disease. New approaches to support evidence-based treatment decisions are required, such as registry trials. Recently, a number of targeted therapies have emerged as viable treatment options in other cancer types, and for some of these, the actionable tumor mutations are also seen in MOC. Thus, a promising alternative approach to provide benefit to current MOC patients involves DNA sequencing to identify a tumor’s unique mutational profile and allow matching to available targeted agents. Such a pipeline can involve special approval to administer a drug already approved for clinical use in other cancer types to a given MOC patient, or their inclusion in existing ongoing clinical trials, such as basket trials encompassing patients with tumors from a range of anatomical sites. Implementation of such personalized medicine can be boosted using improved pre-clinical models, where through a clinical research collaboration a patient’s own tumor cells can be used to a test a range of putative therapies prior to administration in the clinic, enabling selection of the available pharmaceutical/s that give any given patient the best possible chance of cancer remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113(3):331-4. doi:S0090-8258(09)00082-1 [pii] https://doi.org/10.1016/j.ygyno.2009.02.010.

  2. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer. 2008;18(2):209–14. https://doi.org/10.1111/j.1525-1438.2007.01022.x.

    Article  CAS  PubMed  Google Scholar 

  3. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. Lyon: IARC2014.

  4. Hess V, A’Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22(6):1040–4.

    Article  CAS  Google Scholar 

  5. Firat Cuylan Z, Karabuk E, Oz M, Turan AT, Meydanli MM, Taskin S, et al. Comparison of stage III mucinous and serous ovarian cancer: a case-control study. J Ovarian Res. 2018;11(1):91. https://doi.org/10.1186/s13048-018-0464-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(5):480.e1-8. https://doi.org/10.1016/j.ajog.2011.06.049.

    Article  Google Scholar 

  7. Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010;21(12):2377–81. https://doi.org/10.1093/annonc/mdq257.

    Article  CAS  PubMed  Google Scholar 

  8. Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12(11):1071-80. S1470-2045(11)70058-4 [pii]https://doi.org/10.1016/S1470-2045(11)70058-4.

  9. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):945–52. https://doi.org/10.1111/IGC.0b013e3181dd0110.

    Article  PubMed  Google Scholar 

  10. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97(2):436–41. https://doi.org/10.1016/j.ygyno.2004.12.056.

    Article  PubMed  Google Scholar 

  11. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88. https://doi.org/10.1016/s0140-6736(13)62146-7.

    Article  PubMed  Google Scholar 

  12. •• Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020;156(3):552-60. doi:https://doi.org/10.1016/j.ygyno.2019.12.015. Our recent genomic analysis of a large (nearly 200-strong) cohort of MOC, which suggests targeted therapies that may and also may not be appropriate.

  13. Ovarian Cancer (Version 1.2019). National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed March 8 2019.

  14. Santotoribio JD, Garcia-de la Torre A, Canavate-Solano C, Arce-Matute F, Sanchez-del Pino MJ, Perez-Ramos S. Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors. Eur J Gynaecol Oncol. 2016;37(1):26-9.

  15. Lin W, Cao D, Shen K. Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study. Cancer Manag Res. 2018;10:6913–20. https://doi.org/10.2147/CMAR.S186258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lertkhachonsuk AA, Buranawongtrakoon S, Lekskul N, Rermluk N, Wee-Stekly WW, Charakorn C. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors. J Obstet Gynaecol Res. 2020;46(11):2287–91. https://doi.org/10.1111/jog.14427.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med. 2019;380(13):1256–66. https://doi.org/10.1056/NEJMra1813254.

    Article  CAS  PubMed  Google Scholar 

  18. Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013;208(1):46.e1-4. https://doi.org/10.1016/j.ajog.2012.10.863.

    Article  Google Scholar 

  19. Naik JD, Seligmann J, Perren TJ. Mucinous tumours of the ovary. J Clin Pathol. 2012;65(7):580–4. https://doi.org/10.1136/jclinpath-2011-200320.

    Article  CAS  PubMed  Google Scholar 

  20. Muyldermans K, Moerman P, Amant F, Leunen K, Neven P, Vergote I. Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur J Cancer. 2013;49(7):1600–8. https://doi.org/10.1016/j.ejca.2012.12.004.

    Article  CAS  PubMed  Google Scholar 

  21. Gouy S, Saidani M, Maulard A, Faron M, Bach-Hamba S, Bentivegna E, et al. Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. Gynecol Oncol Rep. 2017;22:21–5. https://doi.org/10.1016/j.gore.2017.08.006.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S14–9. https://doi.org/10.1097/IGC.0000000000000296.

    Article  PubMed  Google Scholar 

  23. Thomas G. Revisiting the role of radiation treatment for non-serous subtypes of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book. 2013. doi:https://doi.org/10.1200/EdBook_AM.2013.33.e205.

  24. Smart A, Chen YH, Cheng T, King M, Lee L. Salvage radiation therapy for localized recurrent ovarian cancer. Int J Gynecol Cancer. 2019. https://doi.org/10.1136/ijgc-2019-000247.

  25. • Kumar A, Le N, Gilks CB, Santos JL, Wong F, Swenerton K et al. Survival benefit of adjuvant radiotherapy: an analysis of low-stage invasive ovarian mucinous carcinomas. Int J Gynecol Cancer. 2017;27(9):1819-25. doi:https://doi.org/10.1097/igc.0000000000001124. Recent retrospective study to evaluate the use of radiotherapy in MOC, suggesting potential benefit in Stage 1C-2.

  26. Patel SC, Frandsen J, Bhatia S, Gaffney D. Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011. J Gynecol Oncol. 2016;27(5): e45. https://doi.org/10.3802/jgo.2016.27.e45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Karabuk E, Kose MF, Hizli D, Taskin S, Karadag B, Turan T, et al. Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study. J Gynecol Oncol. 2013;24(2):160–6. https://doi.org/10.3802/jgo.2013.24.2.160.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Anticancer Res. 2005;25(5):3501–5.

    CAS  PubMed  Google Scholar 

  29. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2):105–12.

    Article  Google Scholar 

  30. Nasioudis D, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Ko EM, et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma. Gynecol Oncol. 2019;154(2):302–7. https://doi.org/10.1016/j.ygyno.2019.05.009.

    Article  PubMed  Google Scholar 

  31. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. https://doi.org/10.1056/NEJMoa0908806.

    Article  CAS  PubMed  Google Scholar 

  32. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57. https://doi.org/10.1016/S0140-6736(14)62223-6.

    Article  PubMed  Google Scholar 

  33. Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252. https://doi.org/10.1186/1471-2407-8-252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. •• Gore M, Hackshaw A, Brady WE, Penson RT, Zaino R, McCluggage WG et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. 2019;153(3):541-8. doi:https://doi.org/10.1016/j.ygyno.2019.03.256. The first attempt at a MOC-specific clinical trial to test chemotherapy regimens. Although the trial failed, this paper presents a very thoughtful dissection on the difficulties of undertaking large international clinical trials in rare diseases.

  35. Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100(3):546–51. https://doi.org/10.1111/j.1349-7006.2008.01065.x.

    Article  CAS  PubMed  Google Scholar 

  36. Vici P, Sergi D, Pizzuti L, Mariani L, Arena MG, Barba M, et al. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J Exp Clin Cancer Res. 2013;32(1):49. https://doi.org/10.1186/1756-9966-32-49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yuan SF, Zhang LP, Zhu LJ, Chen WJ, Zheng WE, Xiong JP. Phase II clinical study on the GEMOX regimen as second-line therapy for advanced ovarian cancer. Asian Pac J Cancer Prev. 2013;14(6):3949–53. https://doi.org/10.7314/apjcp.2013.14.6.3949.

    Article  PubMed  Google Scholar 

  38. Shimizu Y, Nagata H, Kikuchi Y, Umezawa S, Hasumi K, Yokokura T. Cytotoxic agents active against mucinous adenocarcinoma of the ovary. Oncol Rep. 1998;5(1):99–101. https://doi.org/10.3892/or.5.1.99.

    Article  CAS  PubMed  Google Scholar 

  39. Ueda Y, Miyatake T, Nagamatsu M, Yamasaki M, Nishio Y, Yoshino K, et al. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study). Eur J Obstet Gynecol Reprod Biol. 2013;170(1):259–63. https://doi.org/10.1016/j.ejogrb.2013.06.035.

    Article  CAS  PubMed  Google Scholar 

  40. Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore. 1998;27(5):650–6.

    CAS  PubMed  Google Scholar 

  41. Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A, et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol. 2018;29(8):1610–3. https://doi.org/10.1093/annonc/mdy198.

    Article  CAS  PubMed  Google Scholar 

  42. Welch S, Spithoff K, Rumble RB, Maroun J. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21(6):1152–62. https://doi.org/10.1093/annonc/mdp533.

    Article  CAS  PubMed  Google Scholar 

  43. Xu W, Rush J, Rickett K, Coward JI. Mucinous ovarian cancer: a therapeutic review. Crit Rev Oncol Hematol. 2016;102:26–36. https://doi.org/10.1016/j.critrevonc.2016.03.015.

    Article  PubMed  Google Scholar 

  44. Sato N, Saga Y, Mizukami H, Wang D, Fujiwara H, Takei Y, et al. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncol Rep. 2012;27(5):1336–40. https://doi.org/10.3892/or.2012.1626.

    Article  CAS  PubMed  Google Scholar 

  45. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009;113(1):21–7. https://doi.org/10.1016/j.ygyno.2008.12.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2008;110(2):140–5. https://doi.org/10.1016/j.ygyno.2008.04.018.

    Article  CAS  PubMed  Google Scholar 

  47. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A et al. Ovarian cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(2):191-226. doi:https://doi.org/10.6004/jnccn.2021.0007.

  48. Pdr Network LLC. PDR prescribers’ digital reference. 2017.

  49. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019;10(1):3935. https://doi.org/10.1038/s41467-019-11862-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468–93. https://doi.org/10.1200/JCO.20.01924.

    Article  PubMed  Google Scholar 

  51. Ahn DH, Barzi A, Ridinger M, Samuelsz E, Erlander MG, Bekaii-Saab TS et al. A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2020;38(15_suppl):TPS4116-TPS. doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS4116.

  52. Affatato R, Carrassa L, Chilà R, Lupi M, Restelli V, Damia G. Identification of PLK1 as a new therapeutic target in mucinous ovarian carcinoma. Cancers (Basel). 2020;12(3). doi:https://doi.org/10.3390/cancers12030672.

  53. Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111–20. https://doi.org/10.1002/path.4088.

    Article  CAS  PubMed  Google Scholar 

  54. Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, et al. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS ONE. 2013;8(4):e61565. https://doi.org/10.1371/journal.pone.0061565.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gilks CB, McAlpine J. Human epidermal growth factor receptor 2 overexpression and amplification in mucinous tumours of ovary. Histopathology. 2011;58(7):1173–4. https://doi.org/10.1111/j.1365-2559.2011.03865.x.

    Article  PubMed  Google Scholar 

  56. Lin WL, Kuo WH, Chen FL, Lee MY, Ruan A, Tyan YS, et al. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann Surg Oncol. 2011;18(8):2388–94. https://doi.org/10.1245/s10434-011-1572-z.

    Article  PubMed  Google Scholar 

  57. Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol. 2011;64(12):1097–101. https://doi.org/10.1136/jclinpath-2011-200082.

    Article  PubMed  Google Scholar 

  58. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433. https://doi.org/10.1186/1471-2407-9-433.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/s0140-6736(10)61121-x.

    Article  CAS  PubMed  Google Scholar 

  60. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46. https://doi.org/10.1016/s1470-2045(16)00150-9.

    Article  CAS  PubMed  Google Scholar 

  61. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264–71. https://doi.org/10.1200/jco.2010.30.8213.

    Article  CAS  PubMed  Google Scholar 

  62. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012(4):Cd006243. doi:https://doi.org/10.1002/14651858.CD006243.pub2.

  63. Jain A, Ryan PD, Seiden MV. Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location. J Natl Compr Canc Netw. 2012;10(9):1076–80. https://doi.org/10.6004/jnccn.2012.0113.

    Article  PubMed  Google Scholar 

  64. Nasioudis D, Alevizakos M, Holcomb K, Witkin SS. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population. Maturitas. 2017;96:45–50. https://doi.org/10.1016/j.maturitas.2016.11.011.

    Article  PubMed  Google Scholar 

  65. Lee J-Y, Jo YR, Kim TH, Kim HS, Kim MA, Kim JW, et al. Safety of fertility-sparing surgery in primary mucinous carcinoma of the ovary. Cancer research and treatment. 2015;47(2):290–7. https://doi.org/10.4143/crt.2014.004.

    Article  PubMed  Google Scholar 

  66. Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, et al. Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma. Obstet Gynecol. 2019;134(6):1253–9. https://doi.org/10.1097/aog.0000000000003579.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Foroughi S, Wong H-l, Gately L, Lee M, Simons K, Tie J et al. Re-inventing the randomized controlled trial in medical oncology: the registry-based trial. Asia-Pacific Journal of Clinical Oncology. 2018;14(6):365-73. doi:https://doi.org/10.1111/ajco.12992.

  68. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360(9332):505-15. doi:https://doi.org/10.1016/s0140-6736(02)09738-6.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kylie L. Gorringe PhD.

Ethics declarations

Conflict of Interest

Olivia Craig declares that she has no conflict of interest. Carolina Salazar declares that she has no conflict of interest. Kylie Gorringe declares that she has no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Gynecologic Cancers

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 20 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Craig, O., Salazar, C. & Gorringe, K.L. Options for the Treatment of Mucinous Ovarian Carcinoma. Curr. Treat. Options in Oncol. 22, 114 (2021). https://doi.org/10.1007/s11864-021-00904-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00904-6

Keywords

Navigation